Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Gilead offers $2.2bn for Myogen

Executive Summary

Gilead has agreed to acquire public cardiovascular therapeutics developer Myogen for $2.2bn in cash ($52.50 per share, a 52% premium to Myogen's market average). The deal value is around 322 times Myogen's 2005 revenues of $6.9mm.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Payment Includes Cash
    • Full Acquisition
    • Intra-Biotech Deal
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register